Inclusion Criteria:- >18 years old

• Disease criteria: Confirmed by Stanford Pathology to be one of the following Non-Hodgkin's Lymphoma subtypes:

  • Chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL)
  • Extranodal marginal zone B-cell lymphoma
  • Nodal marginal zone B-cell lymphoma
  • Splenic marginal zone B-cell lymphoma

• Treatment criteria

  • Untreated: watchful waiting currently appropriate (includes CLL stage 0) o OR
  • Prior treatment: watchful waiting currently appropriate o OR
  • Refractory disease

• Staging within 4 weeks prior to enrollment (SLL, marginal zone lymphoma)

  • CT chest (date)
  • CT abdomen (date)
  • CT pelvis (date)

OR

• Staging within 4 weeks prior to enrollment (CLL: CT not required)

  • Total White Cell Count (WBC) (Value) (date)
  • Absolute Lymphoma Cell Count (ALC) (Value) (date)

  • Measurable disease

    1. (Site)
    2. (Size) OR
  • CLL (only): Elevated Absolute Lymphoma Cell Count
• Disease amenable to biopsy (must check at least one): Li circulating tumor cells
• Li positive bone marrow
• Li palpable involved site (such as lymph node) measuring >1.5 cm

ECOG performance status <2 (Karnofsky >60)

• Status score:

  • Life expectancy of greater than 3 months

  • Patients must have adequate organ and marrow function (EACH must checked "yes") (Date)

    1. Li absolute neutrophil count >1 ,000/uL
    2. Li platelets >30,000/uL
    3. Li total bilirubin within normal institutional limits
    4. Li AST(SGOT) <2.5 X institutional upper limit of normal
    5. Li ALT(SGPT) <2.5 X institutional upper limit of normal
    6. Li creatinine within normal institutional limits OR creatinine clearance >60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential must have negative BetaHCG at enrollment&#xA; Exclusion Criteria:- Patient has had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • Patient has not recovered from adverse events due to agents administered more than four weeks earlier
  • Patient with stable low grade lymphoma has had rituximab within 3 months Patient with relapsed or refractory disease has had rituximab within 1 month
  • Patient has not recovered from adverse events due to surgery performed 4 weeks earlier
  • Patient is receiving any other investigational agent. Known brain metastases
  • Patient has taken any statin within the past 6 months prior to enrollment in the trial
  • Patient currently abuses alcohol
  • Patient currently takes cyclosporin or gemfibrozil Patient has a prior history of rhabdomyolysis
  • Patient as uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patient is pregnant. Note: Patients are not excluded if they are breastfeeding at the time of enrollment, but breastfeeding should be discontinued if the mother is treated with atorvastatin.
  • HIV-positive patients receiving combination anti-retroviral therapy